849934-89-0

Usage

Uses

Used in Organic Chemistry:
2-METHYLSULFANYL-5-(4,4,5,5-TETRAMETHYL-[1,3,2]-DIOXABOROLAN-2-YL)PYRIDINE is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, making it a valuable building block in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-METHYLSULFANYL-5-(4,4,5,5-TETRAMETHYL-[1,3,2]-DIOXABOROLAN-2-YL)PYRIDINE is used as a key component in the development of new drugs. Its ability to form stable complexes with other molecules makes it a promising candidate for the creation of novel therapeutic agents.
Used in Material Science:
2-METHYLSULFANYL-5-(4,4,5,5-TETRAMETHYL-[1,3,2]-DIOXABOROLAN-2-YL)PYRIDINE is employed as a functional component in the synthesis of advanced materials. Its incorporation into the molecular structure of these materials can impart unique properties, such as improved stability or enhanced reactivity, which can be beneficial in various applications.

InChI:InChI=1/C12H18BNO2S/c1-11(2)12(3,4)16-13(15-11)9-6-7-10(17-5)14-8-9/h6-8H,1-5H3

Upstream product

• 51933-78-9 5-bromo-2-(methylsulfanyl)pyridine 
• 73183-34-3 bis(pinacol)diborane 
• 123-91-1 1,4-dioxane 
• 624-28-2 2,5-dibromopyridine 
• 53939-30-3 5-bromo-2-chloropyridine 

Downstream Products

• 849934-68-5 1-(2,4-difluoro-benzyl)-6-[5-(6-methylsulfanyl-pyridin-3-yl)-thiophen-2-yl]-2-oxo-4-trifluoromethyl-1,2-dihydro-pyridine-3-carbonitrile 
• 1416000-41-3 2-(6-(methylthio)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5]naphthyridin-9(10H)-one 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR

The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.

NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

Modulators of LXR

Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.